Literature DB >> 16528526

Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.

Masanori Umeda1, Shinya Okuda, Haruka Izumi, Daisuke Nagase, Yoshinori Fujimoto, Yasuyuki Sugasawa, Chiaki Arai, Kazuhiko Natori, Masako Katoh, Yasunobu Kuraishi.   

Abstract

We studied the serum phosphorus (P) level of 110 patients with multiple myeloma (MM) (age range 42-83 years, median 62 years) and evaluated the relationship between that and other prognostic factors. Serum P level significantly correlated with the prognostic factors that are relevant to renal dysfunction: serum creatinine (P<0.00000001), serum beta2-microglobulin (P=0.00000088), serum uric acid (P=0.0000014), and corrected serum calcium (cCa P=0.000067). Although it also correlated with the percentage of plasma cells in bone marrow nucleated cells (BMPC%) and the hemoglobin (Hb) and leukocyte counts, the significance was less than for the other four prognostic factors. Serum creatinine, BMPC%, leukocyte count, serum uric acid, bone lesions, beta2-microglobulin, and serum cCa were all significantly higher and Hb significantly was lower in the MM patients with hyperphosphatemia (serum P>3.8 mg/dl). The survival time was significantly shorter in these patients (P=0.000087). Multivariate analysis (Cox's proportional hazards regression model) showed that the serum P level is a significant negative prognostic factor in MM patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528526     DOI: 10.1007/s00277-006-0095-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.

Authors:  Bernard Regidor; Regina Swift; Benjamin Eades; Marsiye Emamy-Sadr; Fadi Tarhini; Tanya M Spektor; James R Berenson
Journal:  Ann Hematol       Date:  2020-11-25       Impact factor: 3.673

2.  Phosphate and Cellular Senescence.

Authors:  Ming Chang Hu; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients.

Authors:  Zhong Ye; Juan P Palazzo; Liz Lin; Yinzhi Lai; Fran Guiles; Ronald E Myers; Jin Han; Jinliang Xing; Hushan Yang
Journal:  J Gastroenterol Hepatol       Date:  2013-09       Impact factor: 4.029

4.  Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.

Authors:  Sebastian Gonzalez-McQuire; Meletios-Athanassios Dimopoulos; Katja Weisel; Walter Bouwmeester; Roman Hájek; Marco Campioni; Craig Bennison; Weiwei Xu; Krystallia Pantiri; Marja Hensen; Evangelos Terpos; Stefan Knop
Journal:  MDM Policy Pract       Date:  2019-01-17

5.  Analysis of the Metabolic Characteristics of Serum Samples in Patients With Multiple Myeloma.

Authors:  Haiwei Du; Linyue Wang; Bo Liu; Jinying Wang; Haoxiang Su; Ting Zhang; Zhongxia Huang
Journal:  Front Pharmacol       Date:  2018-08-22       Impact factor: 5.810

6.  Cu and Zn isotope ratio variations in plasma for survival prediction in hematological malignancy cases.

Authors:  Agustina A M B Hastuti; Marta Costas-Rodríguez; Akihiro Matsunaga; Takayuki Ichinose; Shotaro Hagiwara; Mari Shimura; Frank Vanhaecke
Journal:  Sci Rep       Date:  2020-10-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.